Logo for Acumen Pharmaceuticals Inc

Acumen Pharmaceuticals Investor Relations Material

Latest events

Logo for Acumen Pharmaceuticals Inc

Q3 2024

Acumen Pharmaceuticals
Logo for Acumen Pharmaceuticals

Q3 2024

12 Nov, 2024
Logo for Acumen Pharmaceuticals

R&D Day 2024

2 Oct, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Acumen Pharmaceuticals Inc

Access all reports
Acumen Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company primarily engaged in the discovery and development of therapies for the treatment of Alzheimer's disease. The company's most advanced candidate is ACU193, a humanized monoclonal antibody designed to target toxic soluble amyloid-beta oligomers. These amyloid-beta oligomers are associated with the neurodegeneration seen in Alzheimer’s disease patients. Acumen Pharmaceuticals was founded in 1996 and focuses on progressing its immunotherapy approach to offer potential disease-modifying treatments. The company is headquartered in Charlottesville, Virginia, and its shares are listed on the NASDAQ.